CU24593B1 - Formas cristalinas de n-[2-(3-hidroxi-3-metilbutil)-6-(2-hidroxipropan-2-il)-2h-indazol-5-il]-6-(trifluorometil)- piridin-2-carboxamida - Google Patents

Formas cristalinas de n-[2-(3-hidroxi-3-metilbutil)-6-(2-hidroxipropan-2-il)-2h-indazol-5-il]-6-(trifluorometil)- piridin-2-carboxamida

Info

Publication number
CU24593B1
CU24593B1 CU2018000130A CU20180130A CU24593B1 CU 24593 B1 CU24593 B1 CU 24593B1 CU 2018000130 A CU2018000130 A CU 2018000130A CU 20180130 A CU20180130 A CU 20180130A CU 24593 B1 CU24593 B1 CU 24593B1
Authority
CU
Cuba
Prior art keywords
hydroxypropan
indazol
methylbutyl
carboxamide
pyridine
Prior art date
Application number
CU2018000130A
Other languages
English (en)
Other versions
CU20180130A7 (es
Inventor
Dr Nicolas Guimond
Dr Johannes Platzek
Dr Tobias Thaler
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CU20180130A7 publication Critical patent/CU20180130A7/es
Publication of CU24593B1 publication Critical patent/CU24593B1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

<p>La presente invención se refiere a formas cristalinas de N-[2-(3-Hidroxi-3-metilbutil)-6-(2hidroxipropan-2-ii)-2H-indazol-5-il]-6-(trifluorometil)piridin-2-carboxamida, particularmente el hidrato, que es activo como inhibidor de IRAK4 y por lo tanto útil para el tratamiento o la prevención de linfoma, psoriasis, lupus eritematoso, esclerosis múltiple y EPOC, entre otras afecciones.</p>
CU2018000130A 2016-04-29 2017-04-25 Formas cristalinas de n-[2-(3-hidroxi-3-metilbutil)-6-(2-hidroxipropan-2-il)-2h-indazol-5-il]-6-(trifluorometil)- piridin-2-carboxamida CU24593B1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16167650 2016-04-29
EP16167649 2016-04-29
PCT/EP2017/059764 WO2017186700A1 (en) 2016-04-29 2017-04-25 Crystalline forms of n-[2-(3-hydroxy-3-methylbutyl)-6-(2-hydroxypropan-2-yl)-2h-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide

Publications (2)

Publication Number Publication Date
CU20180130A7 CU20180130A7 (es) 2019-06-04
CU24593B1 true CU24593B1 (es) 2022-05-11

Family

ID=58579196

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2018000130A CU24593B1 (es) 2016-04-29 2017-04-25 Formas cristalinas de n-[2-(3-hidroxi-3-metilbutil)-6-(2-hidroxipropan-2-il)-2h-indazol-5-il]-6-(trifluorometil)- piridin-2-carboxamida

Country Status (37)

Country Link
US (2) US10633365B2 (es)
EP (2) EP3448847A1 (es)
JP (2) JP6916207B2 (es)
KR (2) KR102379948B1 (es)
CN (3) CN109071491B (es)
AU (2) AU2017257208B2 (es)
BR (1) BR112018072247A2 (es)
CA (2) CA3022327A1 (es)
CL (2) CL2018003085A1 (es)
CO (2) CO2018011607A2 (es)
CU (1) CU24593B1 (es)
DK (1) DK3448849T3 (es)
DO (1) DOP2018000236A (es)
EA (1) EA038103B1 (es)
EC (1) ECSP18081451A (es)
ES (1) ES2801800T3 (es)
GE (1) GEP20217230B (es)
HU (1) HUE049331T2 (es)
IL (2) IL262391B (es)
JO (2) JOP20170102B1 (es)
LT (1) LT3448849T (es)
MA (1) MA44758A (es)
MX (2) MX2018013227A (es)
NI (1) NI201800111A (es)
PE (2) PE20190172A1 (es)
PH (1) PH12018502288A1 (es)
PL (1) PL3448849T3 (es)
PT (1) PT3448849T (es)
RS (1) RS60419B1 (es)
SG (2) SG11201808686VA (es)
SI (1) SI3448849T1 (es)
SV (1) SV2018005776A (es)
TN (1) TN2018000359A1 (es)
TW (3) TWI671291B (es)
UA (2) UA122882C2 (es)
UY (2) UY37217A (es)
WO (2) WO2017186700A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3705B1 (ar) 2014-11-26 2021-01-31 Bayer Pharma AG إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
CA3016364A1 (en) 2016-03-03 2017-09-08 Bayer Pharma Aktiengesellschaft New 2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs
MX2018013235A (es) 2016-04-29 2019-02-13 Bayer Pharma AG Forma polimorfa de n-{6-(2-hidroxipropan-2-il)-2-[2-(metilsulfonil )etil]-2h-indazol-5-il}-6-(trifluorometil)piridin-2-carboxamida.
CN109071491B (zh) 2016-04-29 2020-08-21 拜耳医药股份有限公司 吲唑的合成
BR112018074919A2 (pt) 2016-06-01 2020-11-03 Bayer Pharma Aktiengesellschaft uso de indazóis 2-substituídos para tratamento e profilaxia de doenças autoimunes.
KR102547834B1 (ko) * 2016-06-01 2023-06-26 바이엘 애니멀 헬스 게엠베하 동물에서의 알레르기성 및/또는 염증성 질환의 치료 및 예방에 유용한 치환된 인다졸
KR20210024543A (ko) 2018-06-25 2021-03-05 치아타이 티안큉 파마수티컬 그룹 주식회사 IRAK4 억제제로서의 이소티아졸로[5,4-d]피리미딘 화합물
KR102392788B1 (ko) 2019-01-08 2022-04-28 주식회사 엘지에너지솔루션 폴더블 사이드 플레이트를 구비하는 배터리 모듈 및 그 제조 방법
CN111499612B (zh) * 2019-01-30 2022-12-30 上海美悦生物科技发展有限公司 一种作为irak抑制剂的化合物及其制备方法和用途
CN113521079A (zh) * 2020-04-20 2021-10-22 上海领泰生物医药科技有限公司 Irak4抑制剂在治疗ali/ards中的应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7163937B2 (en) 2003-08-21 2007-01-16 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
US20100048660A1 (en) 2006-02-10 2010-02-25 Graham Michael Wynne Treatment of duchenne muscular dystrophy
JP5258563B2 (ja) 2006-06-29 2013-08-07 日産化学工業株式会社 αアミノ酸誘導体及びそれを有効成分として含む医薬
CA2663100A1 (en) 2006-09-07 2008-03-13 Biogen Idec Ma Inc. Indazole derivatives as modulators of interleukin-1 receptor-associated kinase
US20120196824A1 (en) 2009-10-09 2012-08-02 Mitsubishi Tanabe Pharma Corporation Therapeutic agent for cerebral infarction
WO2011153588A1 (en) 2010-06-10 2011-12-15 Biota Scientific Management Pty Ltd Viral polymerase inhibitors
US9073892B2 (en) 2010-12-20 2015-07-07 Merck Serono S.A. Indazolyl triazol derivatives
WO2013106254A1 (en) 2012-01-11 2013-07-18 Dow Agrosciences Llc Pesticidal compositions and processes related thereto
EP2928886B1 (en) 2012-12-07 2016-11-02 Boehringer Ingelheim International GmbH New indanyloxydihydrobenzofuranylacetic acids
US9126984B2 (en) * 2013-11-08 2015-09-08 Iteos Therapeutics 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use
TWI667233B (zh) * 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
SG11201605408RA (en) * 2014-01-10 2016-07-28 Aurigene Discovery Tech Ltd Indazole compounds as irak4 inhibitors
JO3705B1 (ar) * 2014-11-26 2021-01-31 Bayer Pharma AG إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
WO2016174183A1 (en) 2015-04-30 2016-11-03 Bayer Pharma Aktiengesellschaft Combinations of inhibitors of irak4 with inhibitors of btk
BR112018000624A2 (pt) 2015-07-15 2018-09-18 Aurigene Discovery Technologies Limited compostos de indazol e azaindazol como inibidores de irak-4
CA3016364A1 (en) 2016-03-03 2017-09-08 Bayer Pharma Aktiengesellschaft New 2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs
EP3219329A1 (en) * 2016-03-17 2017-09-20 Bayer Pharma Aktiengesellschaft Combinations of copanlisib
CN109071491B (zh) 2016-04-29 2020-08-21 拜耳医药股份有限公司 吲唑的合成
MX2018013235A (es) 2016-04-29 2019-02-13 Bayer Pharma AG Forma polimorfa de n-{6-(2-hidroxipropan-2-il)-2-[2-(metilsulfonil )etil]-2h-indazol-5-il}-6-(trifluorometil)piridin-2-carboxamida.
KR102547834B1 (ko) 2016-06-01 2023-06-26 바이엘 애니멀 헬스 게엠베하 동물에서의 알레르기성 및/또는 염증성 질환의 치료 및 예방에 유용한 치환된 인다졸
BR112018074919A2 (pt) 2016-06-01 2020-11-03 Bayer Pharma Aktiengesellschaft uso de indazóis 2-substituídos para tratamento e profilaxia de doenças autoimunes.

Also Published As

Publication number Publication date
PL3448849T3 (pl) 2020-12-14
AU2017257208B2 (en) 2022-01-20
AU2017256659A1 (en) 2018-10-25
KR102409105B1 (ko) 2022-06-16
TW201738233A (zh) 2017-11-01
CU20180130A7 (es) 2019-06-04
WO2017186693A1 (en) 2017-11-02
WO2017186700A1 (en) 2017-11-02
KR20180137498A (ko) 2018-12-27
EA201892407A1 (ru) 2019-05-31
CN109071491B (zh) 2020-08-21
GEP20217230B (en) 2021-03-10
JP2019514924A (ja) 2019-06-06
TWI651316B (zh) 2019-02-21
IL262413B (en) 2021-05-31
JP6821701B2 (ja) 2021-01-27
UY37214A (es) 2017-11-30
TW201738231A (zh) 2017-11-01
JOP20170101B1 (ar) 2022-03-14
US20190152944A1 (en) 2019-05-23
PH12018502288A1 (en) 2019-07-15
CA3022327A1 (en) 2017-11-02
MA44758A (fr) 2019-03-06
IL262413A (en) 2018-12-31
US10633365B2 (en) 2020-04-28
JP2019514921A (ja) 2019-06-06
RS60419B1 (sr) 2020-07-31
EP3448847A1 (en) 2019-03-06
CN112898269A (zh) 2021-06-04
EP3448849A1 (en) 2019-03-06
SG11201809172WA (en) 2018-11-29
CO2018011607A2 (es) 2018-11-22
JOP20170102B1 (ar) 2023-09-17
MX2018013232A (es) 2019-02-13
NI201800111A (es) 2019-08-29
PE20240651A1 (es) 2024-04-04
CO2018011655A2 (es) 2018-11-13
SV2018005776A (es) 2019-03-18
JP6916207B2 (ja) 2021-08-11
ES2801800T3 (es) 2021-01-13
TN2018000359A1 (en) 2020-06-15
LT3448849T (lt) 2020-09-25
CN109071491A (zh) 2018-12-21
ECSP18081451A (es) 2018-11-30
TWI671291B (zh) 2019-09-11
CA3022329A1 (en) 2017-11-02
IL262391A (en) 2018-12-31
EA038103B1 (ru) 2021-07-06
AU2017256659B2 (en) 2021-05-27
PE20190172A1 (es) 2019-02-01
UY37217A (es) 2017-11-30
PT3448849T (pt) 2020-06-30
BR112018072247A2 (pt) 2019-02-12
BR112018072213A2 (pt) 2019-02-12
US10501437B2 (en) 2019-12-10
EP3448849B1 (en) 2020-05-13
AU2017257208A1 (en) 2018-11-01
KR20190002468A (ko) 2019-01-08
US20190144420A1 (en) 2019-05-16
CN109415339A (zh) 2019-03-01
DK3448849T3 (da) 2020-06-29
KR102379948B1 (ko) 2022-03-31
IL262391B (en) 2022-03-01
DOP2018000236A (es) 2019-01-15
SI3448849T1 (sl) 2020-07-31
HUE049331T2 (hu) 2020-09-28
UA123550C2 (uk) 2021-04-21
MX2018013227A (es) 2019-02-13
CL2018003085A1 (es) 2019-02-15
UA122882C2 (uk) 2021-01-13
SG11201808686VA (en) 2018-11-29
TW201936599A (zh) 2019-09-16
CL2018003097A1 (es) 2019-02-15

Similar Documents

Publication Publication Date Title
CU24593B1 (es) Formas cristalinas de n-[2-(3-hidroxi-3-metilbutil)-6-(2-hidroxipropan-2-il)-2h-indazol-5-il]-6-(trifluorometil)- piridin-2-carboxamida
CL2017001362A1 (es) Compuestos de n-((het)arilmetil)-heteroaril-carboxamidas como inhibidores de calicreína plasmática
GT201700035A (es) Compuestos aminopirimidinilo como inhibidores de jak
CU24572B1 (es) Compuestos derivados de 1,2,4-triazolonas 2,4,5-trisustituidas
CU24389B1 (es) Compuestos de heterociclilo bicíclico como inhibidores de irak4
MX2018005292A (es) Inhibidores de acc y usos de los mismos.
EA201890926A1 (ru) ТРИАЗОЛОВЫЕ ИНГИБИТОРЫ АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ И ВАРИАНТЫ ИХ ПРИМЕНЕНИЯ
MX2018001430A (es) Nuevos compuestos biciclicos como inhibidores duales de autotaxina (atx)/anhidrasa carbonica (ca).
EA201490806A1 (ru) Комбинированный состав двух противовирусных соединений
BR112017013448A2 (pt) composições líquidas de herbicidas contendo sulfonilureia
CL2018000375A1 (es) 2-amino-3-fluoro-3-(fluorometil)-6-meti-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1.
MX2018001890A (es) Compuestos biciclicos como inhibidores de autotaxina (atx).
BR112016014020A8 (pt) moduladores de tetra-hidropiridopirazinas de gpr6.
PE20151594A1 (es) Inhibidores de indolamina 2-3 dioxigenasa
UY35951A (es) HETEROARILOS y USOS DE ESTOS
EA201591961A1 (ru) Ингибиторы акк и их применение
EA201591959A1 (ru) Ингибиторы акк и их применение
NZ730603A (en) Mk2 inhibitors and uses thereof
BR112018011709A2 (pt) inibidores bicíclicos de pad4
BR112016014412A2 (pt) Compostos de diaminopirimidil substituído, composições do mesmo, e métodos de tratamento com o mesmo
EA201591960A1 (ru) Ингибиторы акк и их применение
SV2017005462A (es) Compuestos de isoxazol de ácido hidroxámico como inhibidores de lpxc
CL2018000007A1 (es) Compuestos inhibidores de la señalización de la vía de notch
EA201591962A1 (ru) Ингибиторы акк и их применение
MX363846B (es) Moduladores de oligonucleotido de linfoma linfocitico cronico/linfoma de celulas b 11a (bcl11a) y sus usos.